On September 4, 2024 CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, reported its participation in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024, at the Lotte New York Palace in New York City (Press release, CASI Pharmaceuticals, SEP 4, 2024, https://www.prnewswire.com/news-releases/casi-pharmaceuticals-to-participate-in-the-2024-hc-wainwright-global-investment-conference-302237656.html [SID1234646352]). Members of the CASI management team, including Chief Financial Officer Daniel Lang, MD, and Chief Medical Officer Alexander Zukiwski, MD, will host 1×1 investor meetings at the conference.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
A pre-recorded corporate presentation will be available for conference participants to view in "Virtual Room 1" at 7 a.m. Eastern Time on September 9th. Thereafter, the presentation will be available on the Investors page of the CASI corporate website at View Source